The nose, upper airway and obstructive sleep apnea

Annals of Allergy, Asthma & Immunology 

August 2015 Volume 115, Issue 2, Pages 96–102  CME Review

Overall Purpose
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members
Richard D. deShazo, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Discuss present concepts of the role of nasal abnormalities in obstructive sleep apnea
Review clinical studies evaluating the role of rhinitis and therapy of rhinitis in obstructive sleep apnea

Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of
Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health
(NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received
research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. C. Wilhelm, S. Tamanna, M.I. Ullah, R. deShazo, L
Baldwin Skipworth, J.A. Bernstein, and G. Krishnaswamy, have nothing to disclose. Reviewers and Education/Editorial staff have no
relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
08/01/2015
Course expires: 
07/31/2017
Cost:
$0.00
Rating: 
0

Chelle P. Wilhelm, MD, Richard D. deShazo, MDcorrespondenceemail, Sadeka Tamanna, MD, M. Iftekhar Ullah, MD, Leigh Baldwin Skipworth, BA

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
08/01/2015
Course expires: 
07/31/2017

Price

Cost:
$0.00
Please login or create an account to take this course.